Alexis Vandenberghe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexis Vandenberghe has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Aurélien Sokal
Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Auto-Immune and Immune B cells, Université Paris Cité, Université Paris-Est-Créteil, France
2 shared publications - Imane Azzaoui
Service de Médecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France; INSERM U955, Équipe 2, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France
2 shared publications - Matthieu Mahévas
Service de Médecine Interne, Centre National de Référence des Cytopénies Auto‐Immunes de l'Adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP‐HP) Université Paris Est Créteil Créteil France
2 shared publications - Pascal Chappert
Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Université de Paris, Paris, France; Inovarion, Paris, France
2 shared publications - Adrian Gervais
St. Giles Laboratory of Human Genetics of Infectious Diseases, The Rockefeller University
1 shared publication - Agnès Linglart
Université Paris Saclay, Inserm, AP-HP, Service Endocrinologie et Diabète de L'enfant, Hôpital Bicêtre Paris-Saclay , 63 Rue Gabriel Péri 94270, Le Kremlin-Bicêtre
1 shared publication
Latest Publications
- Open Access
Variant-specific spike conformational dynamics shape memory B cell selection during recall
Immune imprinting profoundly shapes antibody responses to breakthrough infections and vaccination against evolving endemic viruses. Current vaccine design primarily focuses on antigen sequence and variant mutations but rarely consider the structural context in which these antigens are being recognized. In this study, we make use of the longitudinal analysis of memory B cell (MBC) responses in boosted individuals enrolled in the COVIBOOST clinical trial to provide a proof of principle that variant-specific conformational dynamics can impact MBC recruitment and protective antibody responses, independently of epitope conservation. Combining functional characterization of MBC-derived monoclonal antibodies, repertoire analysis, epitope mapping and in silico structural modeling of epitope accessibility, we found that the adjuvanted B.1.351 spike vaccine preferentially recalled MBCs targeting exposed receptor-binding domain neutralizing epitopes. This preferential recruitment arises from the more restricted conformational dynamics of the B.1.351 spike compared to the ancestral Hu-1 spike, leading to increased masking of class 4 and 5 cryptic RBD epitopes. These findings demonstrate that antigen conformational dynamics can be leveraged to redirect pre-existing immunity toward neutralizing epitopes upon boost immunization.
Open AccessVariant-specific spike conformational dynamics shape memory B cell selection during recall
Immune imprinting profoundly shapes antibody responses to breakthrough infections and vaccination against evolving endemic viruses. Current vaccine design primarily focuses on antigen sequence and variant mutations but rarely consider the structural context in which these antigens are being recognized. In this study, we make use of the longitudinal analysis of memory B cell (MBC) responses in boosted individuals enrolled in the COVIBOOST clinical trial to provide a proof of principle that variant-specific conformational dynamics can impact MBC recruitment and protective antibody responses, independently of epitope conservation. Combining functional characterization of MBC-derived monoclonal antibodies, repertoire analysis, epitope mapping and in silico structural modeling of epitope accessibility, we found that the adjuvanted B.1.351 spike vaccine preferentially recalled MBCs targeting exposed receptor-binding domain neutralizing epitopes. This preferential recruitment arises from the more restricted conformational dynamics of the B.1.351 spike compared to the ancestral Hu-1 spike, leading to increased masking of class 4 and 5 cryptic RBD epitopes. These findings demonstrate that antigen conformational dynamics can be leveraged to redirect pre-existing immunity toward neutralizing epitopes upon boost immunization.
- Open Access
- 7 November 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (1)
Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
Inborn and acquired deficits of type I interferon (IFN) immunity predispose to life-threatening COVID-19 pneumonia. We longitudinally profiled the B cell response to mRNA vaccination in SARS-CoV-2 naive patients with inherited TLR7, IRF7, or IFNAR1 deficiency, as well as young patients with autoantibodies neutralizing type I IFNs due to autoimmune polyendocrine syndrome type-1 (APS-1) and older individuals with age-associated autoantibodies to type I IFNs. The receptor-binding domain spike protein (RBD)–specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors. Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes. The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients. These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines.
- 7 November 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (1)
Open AccessHuman type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
Inborn and acquired deficits of type I interferon (IFN) immunity predispose to life-threatening COVID-19 pneumonia. We longitudinally profiled the B cell response to mRNA vaccination in SARS-CoV-2 naive patients with inherited TLR7, IRF7, or IFNAR1 deficiency, as well as young patients with autoantibodies neutralizing type I IFNs due to autoimmune polyendocrine syndrome type-1 (APS-1) and older individuals with age-associated autoantibodies to type I IFNs. The receptor-binding domain spike protein (RBD)–specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors. Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes. The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients. These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines.